. 2025 May 31;43(22):2502–2514. doi: 10.1200/JCO-25-00748

TABLE A3.

Change From Baseline to Week 18 in EORTC QLQ-C30 GHS/QoL, QLQ-STO22 Pain, and EQ-5D-5L Scores in the Total PRO FAS Population

Questionnaire	Lenvatinib + Pembrolizumab + Chemotherapy, LSM (95% CI)	Chemotherapy, LSM (95% CI)	Difference in LSM Change^a (95% CI)
QLQ-C30 GHS/QoL	n = 430	n = 420	–4.15 (–7.18 to –1.12)
QLQ-C30 GHS/QoL	–1.72 (–3.95 to 0.50)	2.42 (–0.01 to 4.86)	–4.15 (–7.18 to –1.12)
QLQ-STO22 pain scale	n = 429	n = 418	3.07 (0.21 to 5.93)
QLQ-STO22 pain scale	–5.55 (–7.73 to –3.38)	–8.62 (–10.97 to –6.27)	3.07 (0.21 to 5.93)
EQ-5D-5L VAS	n = 427	n = 416	–0.78 (–3.43 to 1.86)
EQ-5D-5L VAS	–0.80 (–2.76 to 1.15)	–0.02 (–2.14 to 2.10)	–0.78 (–3.43 to 1.86)

Abbreviations: EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; EORTC QLQ-STO22, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach cancer module; EQ-5D-5L VAS, EuroQoL 5-dimension, 5-level visual analog scale; GHS/QoL, Global Health Status/Quality of Life; FAS, full analysis set; LSM, least squares mean; PRO, participant-reported outcome.

^{^a}

For EORTC QLQ-C30 GHS/QoL and EQ-5D-5L VAS, a higher score indicates better HR QoL; for EORTC-QLQ STO22 pain scale, a higher score indicates worsened symptoms.